COPD is a massive topic for the AKT, so getting these classifications and the management ladder down is essential! It’s all about matching the right treatment to the patient's symptoms and their risk of future flare-ups.

Let's start with the foundation: Spirometry. To diagnose COPD, we look for airflow obstruction that isn't fully reversible.

• The Gold Standard: A post-bronchodilator FEV1/FVC ratio < 0.7 (or below the lower limit of normal).
• Unlike asthma, this obstruction doesn't significantly improve after using an inhaler.

I'll pull up some high-yield lessons on COPD management to give you a solid overview of the NICE and GOLD guidelines.

Once you've confirmed the diagnosis with that < 0.7 ratio, we use the FEV1 % predicted to grade the severity of the airflow limitation. This is the GOLD 1-4 classification.

I've put together a quick reference table for these stages below:

While the FEV1 tells us about the lungs' mechanics, the GOLD ABE assessment (which recently replaced the old ABCD system) tells us how the patient is actually doing. We look at two things: Symptoms (using mMRC or CAT scores) and Exacerbation History.

• Group A: Low symptoms, low risk (0-1 moderate exacerbations, no hospitalizations).
• Group B: High symptoms, low risk (0-1 moderate exacerbations, no hospitalizations).
• Group E (Exacerbator): High risk (≥ 2 moderate exacerbations OR ≥ 1 hospitalization), regardless of symptoms.

Now, let's look at the Inhaler Stepwise Therapy. In the UK, we often follow a mix of GOLD and NICE guidelines. The big shift recently has been moving toward Dual Bronchodilation (LABA+LAMA) earlier in the process.

Here is the management pathway for stable COPD:

The flowchart covers the main pharmacological steps, but for the AKT, remember that smoking cessation is the single most effective intervention to slow the decline in FEV1.

Also, keep an eye out for these "Asthmatic Features" in exam questions, as they dictate whether you add an ICS (Inhaled Corticosteroid) early:

• A history of asthma or atopy.
• Blood eosinophils > 0.3 x 10^9/L.
• Significant diurnal variation in Peak Flow.

If a patient is still struggling despite triple therapy, that's when we consider specialist options like Roflumilast (for chronic bronchitis) or Azithromycin prophylaxis (after ensuring they've stopped smoking).

Would you like to try a few practice questions on this to see how it's tested?